Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human TAX2 in relapsed/refractory advanced or metastatic solid tumors
2025-521164-36-00Phase 2Authorised
- Sponsor
- Apmonia Therapeutics
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, open-label trial of TAX2 in ovarian cancer, colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (2 arms), sponsored by Apmonia Therapeutics. Primary endpoints: Dose-limiting toxicities in phase 1 dose escalation and Safety and tolerability at RP2D in phase 2a expansion. Planned start Sep 2026; status: authorised.
02
Drugs
TAX2
03
Conditions
ovarian cancercolorectal cancer (CRC)pancreatic cancer (PC)cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2025-521164-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521164-36-00.